loading page

An unexpected disease course for a patient with diffuse midline glioma
  • +3
  • Vajiranee Malalasekera,
  • Colleen D'Arcy,
  • Cristina Mignone,
  • Alison Wray ,
  • Jeremy Freeman,
  • Jordan Hansford
Vajiranee Malalasekera
The Royal Children's Hospital Melbourne

Corresponding Author:vajiranee.malalasekera@rch.org.au

Author Profile
Colleen D'Arcy
The Royal Children's Hospital Melbourne
Author Profile
Cristina Mignone
The Royal Children's Hospital Melbourne
Author Profile
Alison Wray
The Royal Children's Hospital Melbourne
Author Profile
Jeremy Freeman
The Royal Children's Hospital Melbourne
Author Profile
Jordan Hansford
Royal Children's Hospital
Author Profile

Abstract

Diffuse intrinsic pontine glioma (DIPG), now reclassified as diffuse midline glioma (DMG), is the most common cause of mortality from paediatric central nervous system (CNS) tumours. Diagnosis is made based on characteristic clinical presentation and neuro-imaging findings. Prognosis is poor, with minimal therapeutic options, reflected in a median survival of under 12 months. We present a patient with Pendred syndrome, diagnosed with DMG at 2-years of age with characteristic presentation and neuro-imaging findings, who remains asymptomatic and well at nearly 4-years post diagnosis despite progression of the primary lesion on serial imaging.
Oct 2021Published in Pediatric Blood & Cancer volume 68 issue 10. 10.1002/pbc.29205